Beclamide

Beclamide

SCHEMBL1086327

O=C(CCCl)NCc1ccccc1.O=C(S)N1CCC2(CC1)CN(Cc1cccc(Br)c1)C(=O)O2

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
FAAH O00519 1/20 0.38
HTR1A P08908 1/20 0.37
HTR7 P34969 1/20 0.37
TACR2 P21452 1/20 0.37
TACR1 P25103 1/20 0.37
LMNA P02545 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HPGD P15428 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
RIPK1 Q13546 1/20 0.35
POLB P06746 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Beclamide SCHEMBL1086331 0.88 TACR2 (0.40) HTR1AHTR7TACR2TACR1HPGD
SCHEMBL1086487 0.86 SIRT2 (0.42) KDM4EFAAHTACR2TACR1SMN1; SMN2
Beclamide SCHEMBL1085947 0.85 NR3C2 (0.39) FAAHHTR1AHTR7TACR2TACR1
SCHEMBL1086328 0.82 POLB (0.47) KDM4EFAAHTACR2TACR1LMNA
SCHEMBL1086125 0.80 KDM4E (0.45) KDM4EFAAHTACR2TACR1SIGMAR1
Beclamide SCHEMBL1086666 0.78 KMT2A (0.42) TACR1LMNACYP2C9CYP2C19HPGD
SCHEMBL4509921 0.77 KDM4E (0.46) KDM4EFAAHTACR2TACR1SMN1; SMN2
SCHEMBL1086488 0.77 KDM4E (0.42) KDM4EFAAHTACR2TACR1SIGMAR1
SCHEMBL4256335 0.77 SIRT2 (0.42) KDM4EFAAHTACR2TACR1SMN1; SMN2
SCHEMBL1085987 0.77 HRH3 (0.45) FAAHTACR2TACR1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC KDM4E 2366/4885FAAH 2616/4885HTR1A 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.